Literature DB >> 16322471

Variable phosphorylation states of pigment-epithelium-derived factor differentially regulate its function.

Galia Maik-Rachline1, Rony Seger.   

Abstract

The pigment epithelium-derived factor (PEDF) belongs to the family of noninhibitory serpins. Although originally identified in the eye, PEDF is widely expressed in other body regions including the plasma. This factor can act either as a neurotrophic or as an antiangiogenic factor, and we previously showed that the 2 effects of PEDF are regulated through phosphorylation by PKA and CK2. Here, we studied the interplay between the PKA and CK2 phosphorylation of PEDF, and found that a PEDF mutant mimicking the CK2-phosphorylated PEDF cannot be phosphorylated by PKA, while the mutant mimicking the PKA-phosphorylated PEDF is a good CK2 substrate. Using triple mutants that mimic the PKA- and CK2-phosphorylated and nonphosphorylated PEDF, we found that PEDF can induce several distinct cellular activities dependent on its phosphorylation. The mutant mimicking the accumulative PKA plus CK2 phosphorylation exhibited the strongest antiangiogenic and neurotrophic activities, while the mutants mimicking the individual phosphorylation site mutants had either a reduced activity or only one of these activities. Thus, differential phosphorylation induces variable effects of PEDF, and therefore contributes to the complexity of PEDF action. It is likely that the triple phosphomimetic mutant can be used to generate effective antiangiogenic or neurotrophic drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16322471     DOI: 10.1182/blood-2005-06-2547

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Pigment epithelium-derived factor and its phosphomimetic mutant induce JNK-dependent apoptosis and p38-mediated migration arrest.

Authors:  Alexander Konson; Sunila Pradeep; Cosimo Walter D'Acunto; Rony Seger
Journal:  J Biol Chem       Date:  2010-11-08       Impact factor: 5.157

Review 2.  Pigment epithelium-derived factor as an anticancer drug and new treatment methods following the discovery of its receptors: a patent perspective.

Authors:  Katrina B Manalo; Peter F M Choong; S Patricia Becerra; Crispin R Dass
Journal:  Expert Opin Ther Pat       Date:  2011-01-05       Impact factor: 6.674

3.  Identification of phosphorylation sites on extracellular corneal epithelial cell maspin.

Authors:  Malathi Narayan; Shama P Mirza; Sally S Twining
Journal:  Proteomics       Date:  2011-03-01       Impact factor: 3.984

Review 4.  Pigment epithelium-derived factor as a multifunctional antitumor factor.

Authors:  N I Fernandez-Garcia; O V Volpert; B Jimenez
Journal:  J Mol Med (Berl)       Date:  2006-11-15       Impact factor: 4.599

Review 5.  Negative regulators of angiogenesis: important targets for treatment of exudative AMD.

Authors:  Mitra Farnoodian; Shoujian Wang; Joel Dietz; Robert W Nickells; Christine M Sorenson; Nader Sheibani
Journal:  Clin Sci (Lond)       Date:  2017-07-05       Impact factor: 6.124

6.  Identification of pigment epithelium-derived factor protein forms with distinct activities on tumor cell lines.

Authors:  P Subramanian; M Deshpande; S Locatelli-Hoops; S Moghaddam-Taaheri; D Gutierrez; D P Fitzgerald; S Guerrier; M Rapp; V Notario; S P Becerra
Journal:  J Biomed Biotechnol       Date:  2012-06-04

Review 7.  PEDF and its roles in physiological and pathological conditions: implication in diabetic and hypoxia-induced angiogenic diseases.

Authors:  Xuemin He; Rui Cheng; Siribhinya Benyajati; Jian-xing Ma
Journal:  Clin Sci (Lond)       Date:  2015-06       Impact factor: 6.124

8.  Dual-targeting anti-angiogenic cyclic peptides as potential drug leads for cancer therapy.

Authors:  Lai Yue Chan; David J Craik; Norelle L Daly
Journal:  Sci Rep       Date:  2016-10-13       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.